Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Treasury Shares (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Treasury Shares readings, the most recent being $322690.0 for Q1 2026.

  • On a quarterly basis, Treasury Shares fell 52.4% to $322690.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $322690.0, a 52.4% decrease, with the full-year FY2025 number at $216048.0, down 47.87% from a year prior.
  • Treasury Shares hit $322690.0 in Q1 2026 for Atara Biotherapeutics, up from $216048.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $16.5 million in Q1 2024 to a low of $216048.0 in Q4 2025.
  • Median Treasury Shares over the past 5 years was $677948.0 (2025), compared with a mean of $4.7 million.
  • Biggest five-year swings in Treasury Shares: crashed 96.26% in 2023 and later surged 65.32% in 2024.
  • Atara Biotherapeutics' Treasury Shares stood at $6.7 million in 2022, then crashed by 96.26% to $250709.0 in 2023, then surged by 65.32% to $414470.0 in 2024, then crashed by 47.87% to $216048.0 in 2025, then skyrocketed by 49.36% to $322690.0 in 2026.
  • The last three reported values for Treasury Shares were $322690.0 (Q1 2026), $216048.0 (Q4 2025), and $278347.0 (Q3 2025) per Business Quant data.